Research programme: anti-infectives - SIGA/Innate
Alternative Names: Anti-infectives research programme - SIGA/Innate; Biowarfare therapeutics research programme - SIGA/InnateLatest Information Update: 22 Sep 2014
At a glance
- Originator Innate Pharmaceuticals AB; SIGA Technologies
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Yersinia infections
Most Recent Events
- 26 Apr 2005 Discontinued - Preclinical for Yersinia infections in Sweden (unspecified route)
- 26 Apr 2005 Discontinued - Preclinical for Yersinia infections in USA (unspecified route)
- 07 Nov 2003 Preclinical trials in Yersinia infections in Sweden (unspecified route)